A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: Challenges and implications

被引：18

作者：

Garrison, Louis P., Jr. ^{[1
]}

Carlson, Rick J. ^{[1
]}

Carlson, Josh J. ^{[1
]}

Kuszler, Patricia C. ^{[1
]}

Meckley, Lisa M. ^{[1
]}

Veenstra, David L. ^{[1
]}

机构：

[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA

来源：

DRUG METABOLISM REVIEWS | 2008年 / 40卷 / 02期

关键词：

pharmacogenomics; public policy; economics; regulation; equity; genetic discrimination; gene patents;

D O I：

10.1080/03602530801952500

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This article reviews the regulatory, social, policy, and other issues that will shape the development of pharmacogenomics applications. We identify and analyze 19 key public policy issues, ranging from the economic incentives for linked diagnostic-drug development, to the regulation of tests and drugs, and to privacy and informed consent. Challenging technical, business, and policy-related issues might either hinder progress in the field of pharmacogenomics or potentially accelerate it, depending on how they are addressed and resolved. How well the numerous important stakeholders - both private and public - address these issues will be critical for pharmacogenomics to deliver on its promise.

引用

页码：377 / 401

页数：25

共 46 条

[1] A lay prescription for tailor-made drugs -: focus group reflections on pharmacogenomics [J].

Almarsdóttir, AB ;

Björnsdóttir, I ;

Traulsen, JM .

HEALTH POLICY, 2005, 71 (02) :233-241

[2]

[Anonymous], 2005, EV RISKS DRUG EXP HU

[3]

[Anonymous], 2005, VAL DIAGN INN AD DIF

[4] US Senate Bill 422: The genetic confidentiality and nondiscrimination act of 1997 [J].

Berman, JJ ;

Moore, GW ;

Hutchins, GM .

DIAGNOSTIC MOLECULAR PATHOLOGY, 1998, 7 (04) :192-196

[5] Informed lay preferences for delivery of racially varied pharmacogenomics [J].

Bevan, JL ;

Lynch, JA ;

Dubriwny, TN ;

Harris, TM ;

Achter, PJ ;

Reeder, AL ;

Condit, CM .

GENETICS IN MEDICINE, 2003, 5 (05) :393-399

[6]

*BLUE CROSS BLUE S, 2003, MED TECHN DRIV HEALT

[7] Reporting genetic results in research studies: Summary and recommendations of an NHLBI working group [J].

Bookman, EB ;

Langehorne, AA ;

Eckfeldt, JH ;

Glass, KC ;

Jarvik, GP ;

Klag, M ;

Koski, G ;

Motulsky, A ;

Wilfond, B ;

Manolio, TA ;

Fabsitz, RR ;

Luepker, RV .

AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2006, 140A (10) :1033-1040

[8]

BORCHARDT P, 2005, PHARMACOGENOMICS IN

[9] Genetic testing for a BRCA1 mutation:: Prophylactic surgery and screening behavior in women 2 years post testing [J].

Botkin, JR ;

Smith, KR ;

Croyle, RT ;

Baty, BJ ;

Wylie, JE ;

Dutson, D ;

Chan, A ;

Hamann, HA ;

Lerman, C ;

McDonald, J ;

Venne, V ;

Ward, JH ;

Lyon, E .

AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2003, 118A (03) :201-209

[10] Pharmacogenetics: Ethical issues and policy options [J].

Buchanan, A ;

Califano, A ;

Kahn, J ;

McPherson, E ;

Robertson, J ;

Brody, B .

KENNEDY INSTITUTE OF ETHICS JOURNAL, 2002, 12 (01) :1-15

← 1 2 3 4 5 →